{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:22:28Z","timestamp":1790097748863,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5066-2","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T04:44:54Z","timestamp":1542861894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A systematic review of non-standard dosing of oral anticancer therapies"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-7632","authenticated-orcid":false,"given":"Faouzi","family":"Djebbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Stoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verna Teresa","family":"Lavender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"issue":"7","key":"5066_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14737140.2017.1331131","volume":"17","author":"A Mansinho","year":"2017","unstructured":"Mansinho A, et al. The future of oncology therapeutics. Expert Rev Anticancer Ther. 2017 Jul;17(7):563\u20135. \n                    https:\/\/doi.org\/10.1080\/14737140.2017.1331131\n                    \n                  .","journal-title":"Expert Rev Anticancer Ther"},{"key":"5066_CR2","volume-title":"British national formulary","author":"British Medical Association","year":"2017","unstructured":"British Medical Association. Royal Pharmaceutical Society. In: British national formulary. 73rd ed. London: BMJ group and Pharmaceutical Press; 2017.","edition":"73"},{"key":"5066_CR3","unstructured":"Electronic Medicines Compendium. Summary of Product Characteristics: Glivec 400 mg film-coated tablets. Available from: \n                    https:\/\/www.medicines.org.uk\/emc\/product\/5566\n                    \n                   (Accessed 12th Feb 2018)."},{"key":"5066_CR4","unstructured":"Electronic Medicines Compendium. Summary of Product Characteristics: SUTENT 50 mg hard capsules. Available from: \n                    https:\/\/www.medicines.org.uk\/emc\/product\/7966\n                    \n                   (Accessed 12.02.2018)."},{"issue":"9","key":"5066_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","volume":"94","author":"A Patridge","year":"2002","unstructured":"Patridge A, et al. Adherence to Therapy With Oral Antineoplastic Agents. J Natl Cancer Inst. 2002;94(9):652\u201361 Available from: \n                    https:\/\/academic.oup.com\/jnci\/article\/94\/9\/652\/2520164\/Adherence-to-Therapy-With-Oral-Antineoplastic\n                    \n                   (last accessed: 12.02.2018).","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"5066_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1586\/14737140.2016.1159515","volume":"16","author":"WC Huang","year":"2016","unstructured":"Huang WC, et al. Medication adherence to oral anticancer drugs: systematic review. Expert Rev Anticancer Ther. 2016;16(4):423\u201332. \n                    https:\/\/doi.org\/10.1586\/14737140.2016.1159515\n                    \n                  .","journal-title":"Expert Rev Anticancer Ther"},{"key":"5066_CR7","unstructured":"Electronic Medicines Compendium. Summary of Product Characteristics: Zelboraf 240 mg Film-coated Tablets. Available from: \n                    http:\/\/www.medicines.org.uk\/emc\/medicine\/26056\n                    \n                   (Accessed 12.02.2018)."},{"key":"5066_CR8","unstructured":"National Institute for Health and Care Excellence. NICE Guidance. Available from: \n                    https:\/\/www.nice.org.uk\/guidance\n                    \n                   (Accessed 12.02.2018)."},{"key":"5066_CR9","unstructured":"National Institute for Health and Care Excellence. Technology appraisal guidance. Available from: \n                    https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\n                    \n                   (Accessed 12.02.2018)."},{"issue":"6","key":"5066_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1758834014548187","volume":"6","author":"AJ Dooley","year":"2014","unstructured":"Dooley AJ, Gupta A, Bhattacharyya M, Middleton MR. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol. 2014;6(6):262\u20136 Available from: doi: 10.1177\/1758834014548187.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5066_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/bjh.13072","volume":"168","author":"R Popat","year":"2015","unstructured":"Popat R, Khan I, Dickson J, Cheesman S, Smith D, D\u2019Sa S, Rabin N, Yong K. An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma. Br J Haematol. 2015;168(1):139\u201359 Available from: doi: 10.1111\/bjh.13072.","journal-title":"Br J Haematol"},{"issue":"2","key":"5066_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","volume":"26","author":"MJ Grant","year":"2009","unstructured":"Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Inf Libr J. 2009;26(2):91\u2013108. \n                    https:\/\/doi.org\/10.1111\/j.1471-1842.2009.00848.x\n                    \n                  .","journal-title":"Health Inf Libr J"},{"key":"5066_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"issue":"1","key":"5066_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13643-017-0636-y","volume":"6","author":"F Djebbari","year":"2017","unstructured":"Djebbari F, Stoner N, Lavender V. Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol. Sys Rvs Journal. 2017;6(1):244 Available at: https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-017-0636-y.","journal-title":"Sys Rvs Journal"},{"key":"5066_CR15","unstructured":"Critical Appraisal Skills Programme (CASP). CASP Appraisal Checklists. Available from: \n                    https:\/\/casp-uk.net\/casp-tools-checklists\/\n                    \n                   (Accessed 12.02.2018)."},{"issue":"2","key":"5066_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1365-2141.1991.tb07989.x","volume":"77","author":"A Manoharan","year":"1991","unstructured":"Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol. 1991;77(2):252\u20134.","journal-title":"Br J Haematol"},{"issue":"4","key":"5066_CR17","first-page":"155","volume":"19","author":"M Serpa","year":"2010","unstructured":"Serpa M, Sanabani SS, Bendit I, Seguro F, Xavier F, Barroso CB, Conchon M, Dorlhiac-Llacer PE. Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy. Clin Med Insights: Oncol. 2010;19(4):155\u201362 Available from: doi: 10.4137\/CMO.S6413.","journal-title":"Clin Med Insights: Oncol"},{"issue":"2","key":"5066_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hon.920","volume":"28","author":"M Breccia","year":"2010","unstructured":"Breccia M, Cannella L, Stefanizzi C, Latagliata R, Nanni M, Diverio D, Santopietro M, Federico V, Alimena G. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematol Oncol. 2010;28(2):89\u201392. \n                    https:\/\/doi.org\/10.1002\/hon.920\n                    \n                  .","journal-title":"Hematol Oncol"},{"issue":"11","key":"5066_CR19","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1080\/10428190410001714115","volume":"45","author":"D Zipin","year":"2004","unstructured":"Zipin D, Savage D. Reduced dose Imatinib Mesylate therapy for chronic myeloid leukemia. Leuk Lymphoma. 2004;45(11):2363\u20134 Available from: doi: 10.1080\/10428190410001714115.","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"5066_CR20","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1200\/JCO.2007.10.7722","volume":"25","author":"A Wick","year":"2007","unstructured":"Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. J Clin Oncol. 2007;25(22):3357\u201361 Available from: doi: 10.1200\/JCO.2007.10.7722.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5066_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/10428194.2011.600487","volume":"53","author":"S Mangiacavalli","year":"2012","unstructured":"Mangiacavalli S, Albani G, Caravita T, Cocito F, Pascutto C, Zappasodi P, Bringhen S, Palumbo A, Cazzola M, Corso A. Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed\/refractory multiple myeloma. Leuk Lymphoma. 2012;53(3):514\u20135 Available from: doi: 10.3109\/10428194.2011.600487.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"5066_CR22","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2017.77.1485","volume":"36","author":"E Jonasch","year":"2018","unstructured":"Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Kimryn Rathmell W, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018;36(16):1588\u201393. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.77.1485\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"5","key":"5066_CR23","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1038\/bcj.2015.75","volume":"18","author":"D Russo","year":"2015","unstructured":"Russo D, Malagola M, Skert C, Cancelli V, Turri D, Pregno P, Bergamaschi M, Fogli M, Testoni N, De Vivo A, Castagnetti F, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Cambrin GR, Nicolini G, Abruzzese E, Tiribelli M, Bigazzi C, Usala E, Russo S, Russo-Rossi A, Lunghi M, Bocchia M, D\u2019Emilio A, Santini V, Girasoli M, Di Lorenzo R, Bernardi S, Di Palma A, Cesana BM, Soverini S, Martinelli G, Rosti G, Baccarani M. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J. 2015;18(5):e347 Available from: doi:10.1038\/bcj.2015.75.","journal-title":"Blood Cancer J"},{"issue":"6","key":"5066_CR24","doi-asserted-by":"publisher","first-page":"268.e9","DOI":"10.1016\/j.urolonc.2015.03.008","volume":"33","author":"X Pan","year":"2015","unstructured":"Pan X, Huang H, Huang Y, Liu B, Cui X, Gan S, Ye J, Xu D, Lu C, Zhou Q, Lin L, Hong Y. Sunitinib dosing schedule 2\/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma. Urol Oncol: seminars and original investigations. 2015;33(6):268.e9\u2013268.e15 Available from: doi: http:\/\/dx.doi.org\/10.1016\/j.urolonc.2015.03.008.","journal-title":"Urol Oncol: seminars and original investigations"},{"issue":"3","key":"5066_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.juro.2013.08.090","volume":"191","author":"J Bradley","year":"2014","unstructured":"Bradley J, Atkinson SK, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative Sunitinib schedules. J Urol. 2014;191(3):611\u20138 Available from: doi: http:\/\/dx.doi.org\/10.1016\/j.juro.2013.08.090.","journal-title":"J Urol"},{"issue":"3","key":"5066_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/jjco\/hyt232","volume":"44","author":"T Kondo","year":"2014","unstructured":"Kondo T, Takagi T, Kobayashi H, Iizuka J, Nozaki T, Hashimoto Y, Ikezawa E, Yoshida K, Omae K, Tanabe K. Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma\u2014Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off. Jpn J Clin Oncol. 2014;44(3):270\u20137 Available from: doi:10.1093\/jjco\/hyt232.","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"5066_CR27","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","volume":"26","author":"S Bracarda","year":"2015","unstructured":"Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26(10):2107\u201313 Available from: doi:10.1093\/annonc\/mdv315.","journal-title":"Ann Oncol"},{"issue":"2","key":"5066_CR28","first-page":"88","volume":"83","author":"S Buti","year":"2012","unstructured":"Buti S, Donini M, Lazzarelli S, Passalacqua R. A new modified schedule of Sunitinib for metastatic renal cell carcinoma: a retrospective analysis. Acta Biomed. 2012;83(2):88\u201394 Available from: http:\/\/www.mattioli1885journals.com\/index.php\/actabiomedica\/article\/view\/2367\/1799 (last accessed: 02.04.2018).","journal-title":"Acta Biomed"},{"issue":"5","key":"5066_CR29","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1442-2042.2012.03204.x","volume":"20","author":"B Neri","year":"2013","unstructured":"Neri B, Vannini A, Brugia M, Muto A, Rangan S, Rediti M, Tassi R, Cerullo C. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol. 2013;20(5):478\u201383 Available from: doi: 10.1111\/j.1442-2042.2012.03204.x.","journal-title":"Int J Urol"},{"issue":"10","key":"5066_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/iju.12504","volume":"21","author":"T Ohzeki","year":"2014","unstructured":"Ohzeki T, Fukasawa S, Komaru A, Namekawa T, Sato Y, Takagi K, Kobayashi M, Uemura H, Ichikawa T, Ueda T. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. Int J Urol. 2014;21(10):1065\u20138 Available from: doi: 10.1111\/iju.12504.","journal-title":"Int J Urol"},{"issue":"3","key":"5066_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12032-015-0528-8","volume":"32","author":"H Miyake","year":"2015","unstructured":"Miyake H, Harada K-i, Miyazaki A, Fujisawa M. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. Med Oncol. 2015;32(3):78 Available from: doi:10.1007\/s12032-015-0528-8.","journal-title":"Med Oncol"},{"issue":"2","key":"5066_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/bjd.12615","volume":"170","author":"I Koop","year":"2014","unstructured":"Koop I, Stazger MA, Kapp A, Auschild A, Gutzmer R. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma. Br JDermatol. 2014;170(2):220\u20132 Available from: doi: 10.1111\/bjd.12615.","journal-title":"Br JDermatol"},{"issue":"1","key":"5066_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000369444","volume":"134","author":"HJ Sung","year":"2015","unstructured":"Sung HJ, Lee SR, Choi IK, Park Y, Choi CW, Kim H-J, Yhim H-Y, Kim BS. Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage. Acta Haematol. 2015;134(1):59\u201368. \n                    https:\/\/doi.org\/10.1159\/000369444\n                    \n                  .","journal-title":"Acta Haematol"},{"issue":"1","key":"5066_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12032-010-9767-x","volume":"29","author":"D Binder","year":"2012","unstructured":"Binder D, Buckendahl A-C, Hubner R-H, Schlattmann P, Temmesfeld-Wollbruck B, Beinert T, Suttorp N. Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Med Oncol. 2012;29(1):193\u20138 Available from: doi:10.1007\/s12032-010-9767-x.","journal-title":"Med Oncol"},{"issue":"12","key":"5066_CR35","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s00432-014-1768-2","volume":"140","author":"SH Sim","year":"2014","unstructured":"Sim SH, Keam B, Kim D-W, Kim TM, Lee S-H, Chung DH, Heo DS. The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140(12):2135\u201342 Available from: doi: 10.1007\/s00432-014-1768-2.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5066_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12957-015-0559-9","volume":"13","author":"M Shinoda","year":"2015","unstructured":"Shinoda M, Kishida N, Itano O, Ei S, Ueno A, Kitago M, Abe Y, Hibi T, Yagi H, Masugi Y, Tanabe M, Aiura K, Sakamaoto M, Tanimoto A, Kitagawa Y. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World J Surg Oncol. 2015;13:144 Available from: doi:10.1186\/s12957-015-0559-9.","journal-title":"World J Surg Oncol"},{"issue":"1-2","key":"5066_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3727\/096504015X14452563485986","volume":"23","author":"C Jamison","year":"2016","unstructured":"Jamison C, Nelson D, Eren M, Gauchan D, Ramaekers R, Norvell M, Copur MS. What is the optimal dose and schedule for Dasatinib in chronic myeloid leukemia: two case reports and review of the literature. Oncol Res. 2016;23(1-2):1\u20135 Available from: doi: http:\/\/dx.doi.org\/10.3727\/096504015X14452563485986.","journal-title":"Oncol Res"},{"issue":"19","key":"5066_CR38","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3748\/wjg.v17.i19.2450","volume":"17","author":"G Abbadessa","year":"2011","unstructured":"Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol. 2011;17(19):2450\u20133 Available from: doi:10.3748\/wjg.v17.i19.2450.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"5066_CR39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1097\/JTO.0b013e31821d43a8","volume":"6","author":"H Satoh","year":"2011","unstructured":"Satoh H, Inoue A, Kobayashi K, Maemondo M, Oizumi S, Isobe AG, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T. Low-dose Gefitinib treatment for patients with advanced non-small cell lung Cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol. 2011;6(8):1413\u20137 Available from: doi: 10.1097\/JTO.0b013e31821d43a8.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"5066_CR40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1365-2141.2009.07971.x","volume":"148","author":"M Defina","year":"2010","unstructured":"Defina M, Rondoni M, Gozzetti A, Aprile L, Chitarrelli I, Fabbri A, Lauria F, Bocchia M. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion. Br J Haematol. 2010;148(3):480\u201390 Available from: doi:10.1111\/j.1365-2141.2009.07971.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"5066_CR41","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1080\/10428190600565057","volume":"47","author":"E Faber","year":"2006","unstructured":"Faber E, Nau\u0161ov\u00e1 J, Jaro\u0161ov\u00e1 M, Egorin MJ, Holzerov\u00e1 M, Ro\u017emanov\u00e1 \u0160, Mare\u0161ov\u00e1 I, Divok\u00fd V, Indr\u00e1k K. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leuk Lymphoma. 2006;47(6):1082\u201390 Available from: doi: 10.1080\/10428190600565057.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"5066_CR42","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2169\/internalmedicine.52.8543","volume":"52","author":"A Hata","year":"2013","unstructured":"Hata A, Fujita S, Kaji R, Nanjo S, Katakami N. Dose Reduction or Intermittent Administration of Erlotinib: Which Is Better for Patients Suffering from Intolerable Toxicities? Intern Med. 2013;52(5):599\u2013603 Available from: doi: 10.2169\/internalmedicine.52.8543.","journal-title":"Intern Med"},{"issue":"4","key":"5066_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clgc.2012.04.005","volume":"10","author":"M Bojic","year":"2012","unstructured":"Bojic M, Schmidinger M. Dose matters: the importance of appropriate dosing: a case report on Sunitinib treatment in a patient with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2012;10(4):277\u20139 Available from: doi: https:\/\/doi.org\/10.1016\/j.clgc.2012.04.005.","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"5066_CR44","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1345\/aph.1D184","volume":"37","author":"T Tanvetyanon","year":"2003","unstructured":"Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from Imatinib using once-weekly dosing. Ann Pharmacother. 2003;37(12):1818\u201320 Available from: doi: 10.1345\/aph.1D184.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"5066_CR45","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1158\/2159-8290.CD-13-1038","volume":"4","author":"O Abdel-Wahab","year":"2014","unstructured":"Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB. Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discov. 2014;4(5):538\u201345 Available from: doi: 10.1158\/2159-8290.CD-13-1038.","journal-title":"Cancer Discov"},{"key":"5066_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13104-015-1126-8","volume":"8","author":"A Fukuizumi","year":"2015","unstructured":"Fukuizumi A, Miyanaga A, Seike M, Kato Y, Nakamichi S, Chubachi K, Matsumoto M, Noro R, Minegishi Y, Kunugi S, Kubota K, Gemma A. Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer:a case report. BMC Res Notes. 2015;8:165 Available from: doi :10.1186\/s13104-015-1126-8.","journal-title":"BMC Res Notes"},{"issue":"24","key":"5066_CR47","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.2169\/internalmedicine.54.4996","volume":"54","author":"Y Tsukita","year":"2015","unstructured":"Tsukita Y, Fukuhara T, Kobayashi M, Morita M, Suzuki A, Watanabe K, Noguchi T, Kurata Y, Suno M, Maemondo M. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma. Intern Med. 2015;54(24):3185\u20138 Available from: doi:10.2169\/internalmedicine.54.4996.","journal-title":"Intern Med"},{"issue":"4","key":"5066_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/CAD.0000000000000331","volume":"27","author":"M Saponara","year":"2016","unstructured":"Saponara M, Gatto L, Di Nunno V, Tabacchi E, Fanti S, Di Scioscio V, Nannini M, Gruppioni E, Altimari A, Fiorentino M, Santini D, Ceccarelli C, Zompatori M, Biasco G, Pantaleoa MA. Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anti-Cancer Drugs. 2016;27(4):353\u201363. \n                    https:\/\/doi.org\/10.1097\/CAD.0000000000000331\n                    \n                  .","journal-title":"Anti-Cancer Drugs"},{"key":"5066_CR49","unstructured":"Lea Ann Hansen. Impact of Nonadherence to Cancer Therapy. Journal of Haematology Oncology Pharmacy. Online First. Available at: \n                    http:\/\/www.jhoponline.com\/jhop-issue-archive\/2015-issues\/june-vol-5-no-2?view=article&secid=11003:top-sec-11003&artid=14873:top-14873\n                    \n                   (accessed 05.04.2018)."},{"key":"5066_CR50","unstructured":"Electronic Medicines Compendium. Summary of Product Characteristics: Tarceva 150 mg film-coated tablets. Available from: \n                    https:\/\/www.medicines.org.uk\/emc\/product\/8845\n                    \n                   (Accessed 12th Feb 2018)."},{"key":"5066_CR51","unstructured":"Electronic Medicines Compendium. Summary of Product Characteristics: Revlimid. Available from: \n                    https:\/\/www.medicines.org.uk\/emc\/product\/347\n                    \n                  . (Accessed 12th Feb 2018)."},{"key":"5066_CR52","unstructured":"NHS England. Cancer Drugs Fund. Available from: \n                    https:\/\/www.england.nhs.uk\/cancer\/cdf\/\n                    \n                  . (Accessed 06.04.2018)."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5066-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T19:06:30Z","timestamp":1574363190000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5066-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5066"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5066-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"4 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FD, MPharm (Hons), Oncology MSc, I.Presc. Pre-doctoral Research Fellow. Specialist Cancer Pharmacist. NS, BSc (Hons), M.R.Pharm.S. (SPresc & IPresc), Dip.Clin.Pharm., PhD, FCPP, FFRPS. Professor Cancer Pharmacy. Consultant Cancer Pharmacist. VL, RGN, BSc (Hons), PGCTHE, PhD, FHEA. Senior Lecturer in Cancer Care. Clinical Academic Fellow","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1154"}}